Trastuzumab was included in the SUS in 2012, recommended for the treatment of HER2-positive early-stage breast cancer after surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (when applicable), requiring confirmation of HER-2 status before treatment [13]. This evidence concerns the gene ERBB2 and breast carcinoma.